Sanofi and Regeneron Pharmaceuticals said they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent.

Reuters reports the new list price for Praluent will be $5,850 a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October.

Sanofi and Regeneron said they expect the lower-priced Praluent to be available for pharmacies to order in early March.

They said the new price should improve patient access and result in lower out-of-pocket costs for U.S. consumers.


More videos